Estrogen or Raloxifene for Postmenopausal Osteoporosis Therapy?

摘要

Osteoporotic vertebral fractures cause increased morbidity and mortality in postmenopausal women. Estrogen alone (ERT, estrogen replacement therapy) or combined with progestin (HRT, hormone replacement therapy), and raloxifene, a selective estrogen receptor modulator (SERM), are therapeutic options for osteoporosis. The clinical trial evidence to support fracture efficacy of ERT/HRT and raloxifene are reviewed.